Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

First Edition: February 27, 2014

Today's headlines include a number of stories about Obama past and present administration officials -- notably, former Secretary of State Hillary Clinton and Vice President Joe Biden -- who are stepping up to "sell" people on enrolling in new health law insurance coverage.

27 Feb 2014

Viewpoints: Health law's forgotten taxes; 'lame documentation' by critics; hospital closing crisis

The Affordable Care Act contains at least two economically distinct taxes on labor market activity. Even the experts on the law have failed to recognize all of them (Casey B. Mulligan, 2/26).

27 Feb 2014

Fred Hutchinson, SCCA researchers receive Seattle Business Magazine's 2014 Leaders in Health Care Awards

Researchers at Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance (SCCA) were recognized in several categories of Seattle Business Magazine's 2014 Leaders in Health Care Awards, including the publication's Lifetime Achievement Award, given to Frederick R. Appelbaum, M.D., executive vice president and deputy director of Fred Hutch and president of SCCA.

26 Feb 2014

Biothera’s Phase 2b clinical trial in NSCLC presented at International Association for the Study of Lung Cancer

Biothera presented results of its Phase 2b clinical trial in non-small cell lung cancer (NSCLC) this past weekend to top clinicians and scientists at the invitation-only International Association for the Study of Lung Cancer meeting on targeted therapies in Santa Monica, CA.

26 Feb 2014

Health law attack ads under the microscope

As congressional races heat up, political ads related to the health law move into the realm of fact-checking and demands for proof.

26 Feb 2014

UCLA scientists developed experimental treatment that eradicates acute type of leukemia in mice

A diverse team of scientists from UCLA's Jonsson Comprehensive Cancer Center have developed an experimental treatment that eradicates an acute type of leukemia in mice without any detectable toxic side effects. The drug works by blocking two important metabolic pathways that the leukemia cells need to grow and spread.

25 Feb 2014

Study: Blacks are more likely to have precursor condition than whites

Blacks may be twice as likely as whites to develop multiple myeloma because they are more likely to have a precursor condition known as monoclonal gammopathy of undetermined significance (MGUS), a Mayo Clinic study has found.

25 Feb 2014

Novel two-pronged strategy targeting DNA synthesis treats leukemia in mice

A novel two-pronged strategy targeting DNA synthesis can treat leukemia in mice, according to a study in The Journal of Experimental Medicine.

25 Feb 2014

Cell therapy: A powerful treatment for cancer patients

Investigators from Memorial Sloan Kettering Cancer Center have reported more encouraging news about one of the most exciting methods of cancer treatment today. The largest clinical study ever conducted to date of patients with advanced leukemia found that 88 percent achieved complete remissions after being treated with genetically modified versions of their own immune cells.

24 Feb 2014

War of partisan words ramps up for election season

A conservative group and "dozens of Democrats" are adjusting their messages for the midterm election.

20 Feb 2014

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics, Inc. today reported financial results and recent developments for the quarter and year ended December 31, 2013.

20 Feb 2014

Purdue’s new innovation improves drug therapies by making real-time decisions about treatment options

Oncologists and cancer patients could improve the results of drug therapies by making real-time decisions about treatment options using an innovation developed in Purdue University's College of Pharmacy.

20 Feb 2014

Babies who develop leukemia appear to inherit strong genetic predisposition to disease

Babies who develop leukemia during the first year of life appear to inherit an unfortunate combination of genetic variations that can make the infants highly susceptible to the disease, according to a new study at Washington University School of Medicine in St. Louis and the University of Minnesota.

20 Feb 2014

Experimental drug dinaciclib may improve myeloid leukemia, myeloma therapies

A pre-clinical study led by Virginia Commonwealth University Massey Cancer Center and Department of Internal Medicine researchers suggests that an experimental drug known as dinaciclib could improve the effectiveness of certain multiple myeloma and myeloid leukemia therapies.

19 Feb 2014

Update Pharma's UPI-928 gets FDA orphan drug designation for AML treatment

Update Pharma Inc. today announced that the FDA has approved Orphan Drug Status for the use of UPI-928 for the treatment of Acute Myeloid Leukemia (AML).

18 Feb 2014

Old FDA-approved drugs may hold promise for treatment of rare, drug-resistant cancer

University of Pittsburgh Cancer Institute (UPCI) scientists have shown that old drugs might be able to do new tricks.

14 Feb 2014

Study shows how Bcl-2 cancer-related protein signals cancer cells to live longer

A team of researchers from Case Western Reserve School of Medicine has discovered how the cancer-related protein Bcl-2 signals cancer cells to live longer.

14 Feb 2014

Researchers personalize drug treatments for cholangiocarcinoma using genomic sequencing

Physicians at Mayo Clinic's Individualized Medicine Clinic and researchers at the Translational Genomics Research Institute (TGen) have personalized drug treatments for patients with cholangiocarcinoma using genomic sequencing technologies.

14 Feb 2014

FDA approves Biologics’ IMBRUVICA as oral agent for treatment of patients with CLL

Biologics, a limited distribution network partner for IMBRUVICA™ (ibrutinib), is pleased to announce the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA™ (ibrutinib) capsules as a single, oral agent for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.

14 Feb 2014

New approach for treating leukemia

A group of researchers at the Institute for Research in Immunology and Cancer (IRIC) of Université de Montréal discovered a promising new approach to treating leukemia by disarming a gene that is responsible for tumor progression.

14 Feb 2014

Leukemia News and Research

Further Reading

First Edition: February 27, 2014

Viewpoints: Health law's forgotten taxes; 'lame documentation' by critics; hospital closing crisis

Fred Hutchinson, SCCA researchers receive Seattle Business Magazine's 2014 Leaders in Health Care Awards

Biothera’s Phase 2b clinical trial in NSCLC presented at International Association for the Study of Lung Cancer

Health law attack ads under the microscope

UCLA scientists developed experimental treatment that eradicates acute type of leukemia in mice

Study: Blacks are more likely to have precursor condition than whites

Novel two-pronged strategy targeting DNA synthesis treats leukemia in mice

Cell therapy: A powerful treatment for cancer patients

War of partisan words ramps up for election season

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Purdue’s new innovation improves drug therapies by making real-time decisions about treatment options

Babies who develop leukemia appear to inherit strong genetic predisposition to disease

Experimental drug dinaciclib may improve myeloid leukemia, myeloma therapies

Update Pharma's UPI-928 gets FDA orphan drug designation for AML treatment

Old FDA-approved drugs may hold promise for treatment of rare, drug-resistant cancer

Study shows how Bcl-2 cancer-related protein signals cancer cells to live longer

Researchers personalize drug treatments for cholangiocarcinoma using genomic sequencing

FDA approves Biologics’ IMBRUVICA as oral agent for treatment of patients with CLL

New approach for treating leukemia

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News